房颤伴ACS患者经皮冠状动脉介入术后抗栓研究

Study on Antithrombotic after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation and ACS

随着人口老龄化的加剧,心房颤动(房颤)患者越来越多,房颤伴有血栓风险,死亡率和致残率增高。部分房颤患者因合并急性冠脉综合征(ACS)需行经皮冠状动脉介入术(PCI)治疗,术后需针对房颤和ACS血栓形成的不同机制进行联合抗栓,但是如何平衡出血和血栓风险进而选择合适的策略仍是临床中一项极大的挑战。本文对近年来房颤伴ACS患者PCI术后抗栓治疗的有效性和安全性相关研究进行综述,以期指导临床个体化抗栓治疗方案的选择。

With the aging of the population,more and more patients with atrial fibrillation (AF),atrial fibrillation with thrombosis risk,increased mortality and disability.Many patients with atrial fibrillation undergo percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS).Postoperative antithrombotic therapy is needed for different mechanisms of atrial fibrillation and ACS thrombosis,but how to balance bleeding and the risk of thrombosis and the selection of appropriate strategies remains a major clinical challenge.This article reviews the recent advances in the efficacy and safety of antithrombotic therapy for postoperative PCI in patients with atrial fibrillation and ACS,and guides the selection of clinical individualized antithrombotic regimens.